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Background: Flupirtine is an analgesic with muscle-relaxing properties that activates Kv7 potassium channels. Kv7
channels are expressed along myelinated and unmyelinated peripheral axons where their activation is expected to
reduce axonal excitability and potentially contribute to flupirtine’s clinical profile.
Trial design: To investigate the electrical excitability of peripheral myelinated axons following orally administered
flupirtine, in-vitro experiments on isolated peripheral nerve segments were combined with a randomised, double-blind,
placebo-controlled, phase I clinical trial (RCT).
Methods: Threshold tracking was used to assess the electrical excitability of myelinated axons in isolated segments of human
sural nerve in vitro and motoneurones to abductor pollicis brevis (APB) in situ in healthy subjects. In addition, the effect of
flupirtine on ectopic action potential generation in myelinated axons was examined using ischemia of the lower arm.
Results: Flupirtine (3-30 μM) shortened the relative refractory period and increased post-conditioned superexcitability in
human myelinated axons in vitro. Similarly, in healthy subjects the relative refractory period of motoneurones to APB was
reduced 2 hours after oral flupirtine but not following placebo. Whether this effect was due to a direct action of flupirtine on
peripheral axons or temperature could not be resolved. Flupirtine (200 mg p.o.) also reduced ectopic axonal activity induced
by 10 minutes of lower arm ischemia. In particular, high frequency (ca. 200 Hz) components of EMG were reduced in the
post-ischemic period. Finally, visual analogue scale ratings of sensations perceived during the post-ischemic period were
reduced following flupirtine (200 mg p.o.).
Conclusions: Clinical doses of flupirtine reduce the excitability of peripheral myelinated axons.
Trial registration: ClinicalTrials registration is NCT01450865.
Keywords: Kv7 potassium channel, Flupirtine, Human myelinated axon, A fibre, Randomised controlled trialBackground
Blockade of voltage-dependent sodium channels has been
successful in the treatment of some forms of clinical pain,
e.g. diabetic polyneuropathy, lumbar radiculopathies, com-
plex regional pain syndrome, neuralgic pain and traumatic
peripheral nerve injuries for review: [1]. A group of com-
pounds which might also influence axonal excitability are
synthetic activators of slow axonal Kv7 potassium channels,* Correspondence: johannes.fleckenstein@med.uni-muenchen.de
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distribution, and reproduction in any mediumsuch as flupirtine which has recently been used in the treat-
ment regimens of patients with peripheral neuropathies [2].
The target of such strategies is the KV7 (formerly KCNQ/
M) family of potassium channels.
Five genes (KCNQ1-5) encode Kv7 subunits, each with
6 trans-membrane spanning domains, a P-loop and a con-
served A-domain in the cytoplasmic C-terminal region.
Neurones express four Kv7 subunits (Kv7.2-Kv7.5) that
co-assemble to form either homo- or hetero-tetrameric
voltage-gated channels [3,4] and channel activity can be
readily inhibited by agonist action at Gq/11-coupled
receptors [5]. In rodents, Kv7.2 is found at nodes ofntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the spinal ventral horn [7], while Kv7.3 is expressed in
myelinating Schwann cells [8]. In myelinated axons of
smaller calibre, both Kv7.2 and Kv7.3 subunits are found
nodally [6] Similarly, Kv7.2, Kv7.3 and Kv7.5 are found
along somatic unymelinated axons [9] visceral unmyeli-
nated axons [10] and in baroreceptor nerve terminals [11].
The presence of axonal Kv7 subunits has also been con-
firmed functionally in peripheral nerve. The synthetic Kv7
channel activator retigabine shifts the activation of myelin-
ated axons in the hyperpolarizing direction [6] and reduces
the electrical threshold of unmyelinated axons in human
sural nerve [12]. Similarly, flupirtine increases the electrical
threshold of myelinated axons in rat sural [13] nerve.
Kv7 channels activate in response to depolarization,
beginning at around -60 mV, and deactivate slowly but
do not inactivate [4]. The slow time course of voltage ac-
tivation and lack of inactivation of Kv7 channels suggests
that one role of Kv7 in peripheral axons may be to limit
the extent of repetitive burst discharges. Consistent with
this, the phenotype accompanying dominant-negative
mutations in KCNQ2 (Kv7.2) and on occasion KCNQ3
(Kv7.3) is benign familial neonatal convulsions BFNC;
[14]. In some patients with BFNC, myokymia symptoms
are reported and characterized by spontaneous involun-
tary muscle fasciculations [7,15-17]. Myokymic symp-
toms arise from hyperexcitability of motoneurones
expressing Kv7.2 [18] and are associated with a point
mutation of arginine at position 207 in KCNQ2 that
neutralizes the third of six positive charges in the
voltage-sensing S4 segment, leading to a slowing and a
depolarizing shift of activation [7,17].
Pharmacological activation of Kv7 thus offers an im-
portant therapeutic strategy for reducing hyperexcitabil-
ity. The current study has examined the profile of action
of the Kv7 channel activator flupirtine by examining its
effects on peripheral myelinated axons at clinically
achieved concentrations.
Materials and methods
Ethics
Protocol and consent forms were approved by the
Committee for Ethics of the University of Munich and
ethical approval to study drug effects in healthy volun-
teers was provided by the German Federal Institute for
Drugs and Medical Devices. In accord with the declar-
ation of Helsinki (Seoul 2008) all participants provided
their written informed consent prior to participation in
the study. ClinicalTrials registration is NCT01450865.
In vitro studies
Procurement and preparation of human sural nerve
Segments of sural and peroneal nerve were obtained
from patients previously scheduled for biopsy (n=7; 1female, 6 male, age range: 48–80). The diagnosis pre-
cipitating biopsy was typically polyneuropathy of
unknown aetiology. Patients were informed about the
procedure by an anaesthesiologist prior to surgery.
Upon surgical removal nerve segments were immedi-
ately placed in physiological solution containing (in
mM): 117 NaCl, 3.6 KCl, 2.5 CaCl2, 1.2 MgCl2, 1.2
NaH2PO4, 25 NaHCO3, 11 D-glucose (bubbled to pH
7.4 with 95 % O2 – 5 % CO2).Immunohistochemistry Individual fascicles were iso-
lated from nerve segments and teased apart with fine
forceps. After incubating in PBS containing 0.3% col-
lagenase (30 min, room temp.) and washing twice in
PBS, preparations were mounted on gelatine-coated
slides, dried overnight and fixed in 4% paraformalde-
hyde for 30 minutes. For immunostaining, prepara-
tions were blocked in PBS containing 0.2% Triton
100 and 10% natural goat serum at room temperature
for 40 minutes, followed by overnight incubation at
4°C with rabbit anti-KCNQ2-N antibodies diluted
1:200 [19] raised and affinity-purified as previously
described [19,20]. KCNQ2 antibodies were directed
against residues 13–37 of the conserved intracellular
N-terminal region [21,22]. Monoclonal antibodies
against peripherin (diluted 1:200) and the alpha subu-
nits of voltage-gated (NaV) sodium channels (panNaV,
diluted 1:200) were used. After incubation with the
primary antibody, slides were washed three times in
PBS and incubated with fluorescein- and rhodamine-
conjugated donkey cross-affinity-purified secondary
antibodies at room temperature for two hours (all
diluted 1:400). Slides were then washed three times
with PBS and covered with Aqua-Poly/Mount Cover-
slipping medium. Digital images were taken with a
laser-scanning confocal microscope (Bio-Rad MRC-1024,
Bio-Rad Laboratories GmbH, Munich, Germany). No evi-
dence of antibody cross-reactivity was observed in multila-
beling experiments with single label and secondary-only
controls.Threshold tracking Nerve fascicles were mounted be-
tween stimulating and recording electrodes in an organ
bath perfused continuously with physiological solution
tempered to 32°C. Constant current was used for stimu-
lation (1 ms, A395, WPI, Sarasota, USA) and extracel-
lular signals were amplified (NPI, Tamm, Germany),
filtered (30 Hz - 1.3 kHz), sampled (BNC 2120, National
Instruments, USA) and stored to disk.
Electrical excitability of myelinated axons was assessed
using the TRONDXS4 protocol in QTRAC (© Prof. Bostock,
Institute of Neurology, London, UK).
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Study design Volunteers were recruited for a rando-
mised, double-blind, placebo-controlled, two-way, cross-
over clinical phase I trial (RCT) to investigate the effect
of oral flupirtine on the electrical excitability of periph-
eral myelinated axons. Exclusion criteria were: ongoing
medication, prevailing organic disease, previous forearm
trauma, primary organ failure, pregnancy or breast-
feeding. All female participants were subject to a preg-
nancy test (Cyclotest, UEBE, Wertheim, Germany) prior
to inclusion.
Subjects were assigned randomly to a study arm in
accordance with an algorithm developed by the Institute
of Medical Information Technology, Biometry and
Epidemiology, University of Munich, Germany (IBE),
stratifying for gender. Subjects received a set of sealed
sequentially numbered pill-boxes each containing either
flupirtine or placebo tablets to be taken prior to the
recording sessions. Both the subjects and study physi-
cians were blind to the group allocation.
Preliminary results indicated that a sample size of 12
would be needed to detect a decrease in the primary
outcome measure (RRP) with 80% power at a signi-
ficance level of 5%. With provision for drop-outs,
20 subjects were recruited, with an allocation ratio
of 1:1.
Participants were evaluated on seven occasions in
which motor axon excitability parameters and ischemic
EMG signals were recorded (Additional file 1: Figure
S1). The first 3 recording sessions, scheduled not less
than 48 hours apart, were used to establish baseline
values. The 4th recording session comprised 2 sequential
recordings of axonal excitability, one immediately prior
to pharmacologic intervention and a second two hours
after. EMG during ischemia was only recorded after
medication. The 5th session was a control recording per-
formed 48 hours after the 4th. The 6th recording session
was scheduled 7 ± 1 days after the 5th and comprised 2
sequential recordings immediately before and 2 hours
after medication. The final (7th) recording session was a
control recording performed 48 hours after the 6th. A
pain questionnaire was assessed after the 3rd, the 4th and
the 6th session.
At the time of examination, subjects lay comfortably
in a temperature controlled room.Outcome measures The primary outcome measure was
the relative refractory period (RRP) as determined with
threshold tracking. All other indices were considered
secondary outcome measures.Threshold tracking All experiments were performed by
the same examiner. Skin temperature was determined atthe wrist at the end of each recording session using a
thermocouple (Voltcraft, Hirschau, Germany).
The median nerve of the right hand was used for
nerve excitability studies. A gel disc electrode
(H92SG, Kendall-Arbo, Neustadt, Germany) posi-
tioned at the wrist between palmaris longus and
flexor carpi radialis tendons served as the cathode.
The anode was placed over the course of the median
nerve approximately 2 cm proximal to the cathode.
EMG from abductor pollicis brevis (APB) was re-
corded from one electrode situated over the motor point
and a second electrode over the proximal interphalangeal
joint.
Constant current pulses (DS5, Digitimer, UK) were
used to determine electrical excitability in QTRAC using
the TRONDXM4 protocol with same measures as for
in vitro experiments (see above). The EMG signal was
amplified (gain 200-500x), filtered (bandpass 0.3 Hz to
10 kHz) and sampled at 50 kHz (BNC-2120, National
Instruments, Austin, USA).Ischemia A cuff around the upper arm inflated
to >200mmHg was used to examine flupirtine and pla-
cebo effects on ischemic and post-ischemic EMG from
APB. Muscle fasciculations are known to appear in some
subjects upon recovery from a 10 minute period of is-
chemia of the lower arm with the intensity and inci-
dence increasing with the period of ischemia [23]. EMG
signals were filtered, amplified and sampled at 20
kHz (ADInstruments GmbH, Spechbach, Germany).
EMG was recorded continuously over a 21 minute
period comprising one minute baseline followed by
10 minutes of ischemia and a further 10 minutes
post-ischemia.
Volunteers rated the intensity of sensations before,
during and after ischemia on a visual analogue scale
(0–100 mm with 0 being no pain and 100 being maximal
pain) and completed the Short Form McGill Pain
Questionnaire (SF-MPQ) for sensations experienced
during the first 5 minutes following release of the
pressure cuff, i.e. post-ischemia. The SF-MPQ comprises
eleven sensory and four affective pain descriptors that
can be ranked in intensity from 0 = none to 3 = severe
[24]. The sum of ranked values provides a sensory
(SPRI; 0–33), an affective (APRI; 0–12) and a total
pain score (TPRI; 0–45).Data analysis
Axonal excitability Electrical excitability of myelinated
axons determined both in vitro and in vivo were ana-
lyzed off-line with the MEM routine in QTRAC. Six
parameters were taken directly from the QTRAC ana-
lysis, namely the strength-duration time constant,
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excitability at 5 and 7 ms and during the 90-100 ms
hyperpolarizing and depolarizing current pulses of the
threshold electrotonus. The relative refractory period
was determined using custom written software in Igor
Pro (WaveMetrics, Lake Oswego, USA) by determining
the first zero crossing of an exponential fit to recovery
cycle data points less than 5 ms.
Electromyography Rectified and integrated EMG was
used to quantify continuous signals. EMG power was
calculated by discrete fast Fourier transform (FFT) of
EMG recorded in the time domain.
Statistics
Mean and standard deviation are used for population
descriptors while mean and standard error of the mean
are indicated for comparisons between groups. Normal-
ity was tested using Kolmogorov-Smirnov analysis. For
parametric datasets Student’s paired t-test was used for
pairwise comparisons. Unpaired datasets were compared
using one-way ANOVA with post hoc Tukey-Kramer.
Non-parametric datasets were analysed using Wilcoxon
ranked sign test for paired data, and Kruskal-Wallis
ANOVA with post hoc Mann–Whitney-U tests for
non-paired data. The level of statistical significance is
indicated throughout with * for p < 0.05 and ** for
p < 0.01.
Chemicals and drugs
Triton 100, natural goat serum and the monoclonal anti-
body against panNaV were purchased from Sigma-
Aldrich (Munich, Germany), the monoclonal antibody
against peripherin was obtained from Chemicon (EMD
Millipore Corporation, Billerica, USA). Anti-KCNQ2/
Kv7.2 was kindly provided by M. Schwake (Kiel, Germany).10 µm
10 µm
i ii iii
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Figure 1 Immunohistochemistry of Kv7 channels in human sural nerv
nodes of Ranvier as well as in unmyelinated fibres of human sural nerve w
bright field illumination (i) shows immunoreactivity for Kv7.2 (ii and merge
show immunoreactivity for Kv7.2 (ii and merge v). In a separate prepara
specific voltage-gated sodium channel marker PanNav (vi) colocalise atFluorescein-and rhodamine-conjugated donkey cross-
affinity-purified secondary antibodies were purchased
from Invitrogen (Paisley, UK). Aqua-Poly/Mount Cov-
erslipping Medium was purchased from Polysciences
Europe (Eppelheim, Germany). Flupirtine (in vitro)
was purchased from Sigma (Taufkirchen, Germany)
and XE991 from Biotrend (Wangen, Switzerland). The
final concentration of test substances used in vitro was
achieved by diluting stock solutions in the perfusing
solution on the day of the experiment.
Blinded oral preparations of flupirtine 100 mg (AWD.
pharma GmbH & Co.KG, Radebeul, Germany) and pla-
cebo tablets (7 mm capsules (Winthrop Arzneimittel
GmbH, Frankfurt, Germany) were performed by the
Pharmaceutical Department, University of Munich en-
capsulating both in gelatine (size 00, white opaque;
Shionogl Qualicaps S.A., Alcobendas / Madrid, Spain)
containing lactose, ferric oxide and food colouring
E172 (all Fagron GmbH, Barsbüttel, Germany).Results
Immunohistochemistry of human A-fibre
Using polyclonal antibodies, Kv7.2 subunits could be
identified at nodes of Ranvier in teased fibre prepara-
tions of human sural nerve (Figure 1). Nodes of Ranvier
were identified using DIC images to delineate myelinat-
ing Schwann cells and co-labeling with mouse PanNaV
(voltage-gated sodium channels, Figure 1 vi-viii). Not-
ably, Kv7.2 was also detected along unmyelinated fibres
co-labeled with peripherin (Figure 1 iv, v).In vitro assessment of human A-fibre excitability
Recordings were made from twenty-one individual fascicles
of human sural nerve. The average compound A-fibre re-
sponse to supra-maximal electrical stimulation (0.1 ms,iv v
e fascicles in vitro. The presence of Kv7.2 subunits at peripheral
as verified immunohistochemically. A node of Ranvier evident under
iii). In addition, unmyelinated fibres labelled with peripherin (iv) also
tion, Kv7.2 immunoreactivity (vii) and immunoreactivity for the non-
a node of Ranvier (merge viii). Scale bars indicate 10 μm.
Table 1 Electrical excitability parameters for myelinated axons in human sural nerve in vitro
Baseline (n = 21) Flupirtine 3μM (n = 7) Flupirtine 10 μM (n = 8) Flupirtine 30 μM (n = 16) XE 911 10μM (n = 9) ANOVA (df)F, p
Strength-duration time
constant (ms)
0.11 ± 0.02 0.19 ± 0.03 0.13 ± 0.02 0.10 ± 0.01 0.16 ± 0.03 (3:43)2.00, 0.13
Rheobase (mA) 8.53 ± 2.55 6.47 ± 2.89 6.50 ± 1.76 6.54 ± 1.16 9.35 ± 1.96 (3:43)0.22, 0.88
Relative Refractory Period
RRP (ms)
4.40 ± 0.37 3.30 ± 0.16 2.83 ± 0.17* 2.55 ± 0.13** 3.67 ± 0.30 (3:48)8.61, < 0.01
Refractoriness at 2 ms (%) 76.61 ± 21.07 50.58 ± 18.13 42.74 ± 21.28 45.44 ± 21.86 44.03 ± 5.21 (3:48)0.57, 0.64
Refractoriness at 2.5 ms (%) 30.43 ± 5.63 18.69 ± 5.96 10.47 ± 7.16* 3.19 ± 3.91** 19.46 ± 4.29 (3:48)5.39, < 0.01
Superexcitability at 5 ms (%) −6.61 ± 1.92 −14.04 ± 1.87 −16.20 ± 1.18** −19.00 ± 1.180** −10.83 ± 2.30 (3:48)11.56, < 0.01
Superexcitability at 7 ms (%) −11.04 ± 1.72 −16.74 ± 1.86 −18.01 ± 1.27 −20.25 ± 1.22** −14.64 ± 2.11 (3:48)7.31, < 0.01
Depolarisation TEd
(90–100 ms)
34.86 ± 1.81 32.48 ± 4.11 32.26 ± 3.04 32.33 ± 2.86 35.96 ± 2.33 (3:47)0.27, 0.85
Hyperpolarisation TEh
(90–100 ms)
−73.57 ± 6.79 −72.99 ± 9.23 −68.42 ± 5.44 −85.15 ± 19.30 −108.79 ± 32.65 (3:47)0.27, 0.85
Electrical excitability parameters determined for myelinated axons in human sural nerve in vitro before (Baseline) and during bath application of the Kv7 channel activator flupirtine (3-30 μM) and Kv7 channel blocker
XE991 (10 μM). Data were analysed by one-way-ANOVA (rightmost column) and differences for individual groups relative to baseline were determined with post-hoc Tukey-Kramer tests with the levels of significance
indicated in each column as * for p < 0.05 and for p < 0.01 respectively. Flupirtine reduced the RRP, the refractoriness at 2.5 ms, the magnitude of post-spike superexcitability at 5 ms and at 7 ms in a concentration-
dependent manner but had no effect on the de- and hyperpolarizing threshold electrotonus.
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Figure 2 Effects of Kv7 channel activation and blockade on the recovery cycle of electrical excitability. Stimulus–response curves were
obtained using unconditioned test stimuli of 1 ms duration. These established the maximal CMAP to supramaximal nerve stimulation and the size
of the submaximal target CMAP (~ 40% of maximum). The stimulus current necessary to produce the target potential using a 1 ms test stimulus
is referred to as the “threshold” for that potential. Electrical excitability, i.e. the current required to maintain a 40% compound A-fibre action
potential response, was determined at discrete interstimulus intervals following a supra-maximal stimulus (A). The representative example in
panel B illustrates the concentration-dependent changes in the recovery cycle observed with bath application of flupirtine (3-30 μM) and their
reversal following selective Kv7 channel blockade with XE991 (10 μM). Changes in the recovery cycle of A-fibres were quantified with the
empirically determined values of refractoriness at 2 ms (D) and 2.5 ms (E) and excitability at 5 ms (F) and 7 ms (G). The relative refractory period
(C) was determined respectively by linear interpolation and first-order exponential fits (see Methods). The RRP (p < 0.01) was reduced in a
concentration-dependent manner (C). Flupirtine (30 μM) also reduced refractoriness at 2.5 ms (E; p < 0.01) but not at 2 ms (D). Similarly, flupirtine
produced a concentration-dependent increase in the magnitude of post-spike superexcitability at 5 ms (F; p < 0.01 for flupirtine 10 μM and
30 μM) and at 7 ms (G; p < 0.01; for flupirtine 30 μM).
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half-maximum of 0.82 ± 0.05 ms.
Pooled data for each electrical excitability parameter
determined using the TRONDXS4 protocol in QTRAC is
shown in Table 1. Under control conditions, the strength-
duration time constant was 0.11 ± 0.02 μs and the rheo-
base current 8.53 ± 2.55 μA. ANOVA indicated that nei-
ther flupirtine (3-30 μM; strength-duration time constant
F (3:43) 2.00, p = 0.13; rheobase F (3:43) 0.22, p = 0.88)
nor XE991 (10 μM; strength-duration time constant
F (1:26) 1.45, p = 0.24; rheobase F (1:26) 0.27, p = 0.87)
had a significant effect on these indices of excitability.
Similarly, threshold changes observed during applicationof depolarizing and hyperpolarizing conditioning currents
were also not significantly affected by flupirtine (<30μM,
see Table 1).
Flupirtine (10-30 μM) did however reduce the RRP
(ANOVA F (3:48) 8.61, p < 0.01) determined in human
A-fibres in vitro and this in a concentration-dependent
manner (see Figure 2B&C, Table 1; post-hoc Tukey-Kra-
mer p < 0.01for 10 μM and 3 μM). Importantly, these
effects could be reversed by bath application of the spe-
cific Kv7 channel blocker XE911 (10 μM; Figure 2 B&C
and Table 1; ANOVA F (3:36) 7.46, p < 0.01; post-hoc
Tukey-Kramer p < 0.05 for flupirtine 30 μM). Flupirtine
(30 μM) also reduced refractoriness at 2.5 ms
Table 2 Electrical excitability parameters for motoneurones to APB in vivo (n = 20)
Baseline Flupirtine 200 mg Placebo Control Paired t-test p,
baseline vs. flupirtine
Strength-duration time constant (ms) 0.48 ± 0.01 0.47 ± 0.01 0.47 ± 0.01 0.47 ± 0.01 0.18
Rheobase (mA) 2.87 ± 0.14 3.04 ± 0.18 2.67 ± 0.15 2.82 ± 0.14 0.20
Relative Refractory Period (RRP ms) 3.40 ± 0.10 3.23 ± 0.09 3.45 ± 0.12 3.54 ± 0.13 < 0.01
Refractoriness at 2 ms (%) 165.00 ± 13.96 105.83 ± 10.12 169.77 ± 33.36 138.68 ± 9.49 0.01
Refractoriness at 2.5 ms (%) 66.27 ± 8.86 40.09 ± 6.20 60.28 ± 8.88 60.21 ± 5.84 0.02
Superexcitability at 5 ms (%) −24.57 ± 1.49 −24.73 ± 1.55 −24.11 ± 1.99 −23.28 ± 1.54 0.89
Superexcitability at 7 ms (%) −27.12 ± 1.42 −25.69 ± 1.67 −27.05 ± 1.57 −26.71 ± 1.32 0.09
Depolarisation TEd (90–100 ms) 40.04 ± 0.78 40.37 ± 4.25 40.23 ± 1.11 39.74 ± 0.96 0.69
Hyperpolarisation TEh (90–100 ms) −107.61 ± 3.01 −106.31 ± 2.82 −107.07 ± 4.63 −106.30 ± 2.92 0.50
Skin Temperature (°C) 31.89 ± 0.22 32.20 ± 0.29 31.95 ± 0.32 31.74 ± 0.24 0.13
Electrical excitability parameters determined for motor axons to abductor pollicus brevis in healthy subjects. Values are indicated for recordings made before
(Baseline), 2 hours after oral flupirtine (200 mg p.o.) or placebo and 48 hours subsequent to this (post-Control). Skin temperature was determined with a
thermocouple placed on the skin at the site of stimulation above the median nerve at the end of each recording session. Data were analysed with Student’s
paired t-tests; * and ** indicate levels of significance for p < 0.05 and p < 0.01 respectively. Oral flupirtine reduced the RRP and the refractoriness at 2 ms and
2.5 ms., but had neither effect on the magnitude of superexcitability at both 5 and 7 ms nor the de- and hyperpolarizing threshold electrotonus. There were no
changes in peoples skin temperature throughout the experiment.
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Tukey-Kramer p < 0.01). Similarly, flupirtine produced a
concentration-dependent increase in the magnitude of
post-spike superexcitability at 5 ms (Figure 2F and Table 1;
ANOVA F (3:48) 11.56, p < 0.01; post-hoc Tukey-Kramer
p < 0.01 for flupirtine 10 μM and 30 μM) and at 7 ms
(Figure 2G; ANOVA F (3:48) 7.31, p < 0.01; post-hoc
Tukey-Kramer p < 0.01 for flupirtine 30 μM). Since the
RRP is determined from a fit to 3 or more data points, we
consider this the most reliable index of changes in
excitability.
In vivo assessment of human A-fibre excitability
Twenty volunteers (10 male, 10 female; age 28.3 ± 4.4
years) were randomly allocated to a study arm and
received both placebo and flupirtine (200 mg p.o.) cap-
sules to be taken in a cross-over design. The trial was
enroled between October 2009 and August 2010. None
of the subjects dropped out, all subjects received the
allocated interventions and the follow-up was complete.
Statistical analysis of electrical excitability datasets
from the initial three recording sessions revealed no
time dependent differences in any of the excitability
parameters and further comparisons between this ‘base-
line’ dataset and each of the two pre interventional ses-
sions also showed no differences amongst excitability
parameters. Consequently, all five baseline datasets were
pooled and used as the baseline values for statistical
comparisons.
Compound muscle action potential (CMAP) responses
were recorded from APB in response to supra-maximal
electrical stimulation (4.40 ± 0.22 mA) in 20 volunteers.
CMAPs had an amplitude of 8.59 ± 0.54 mV and a la-
tency to half-maximum of 7.40 ± 0.22 ms. The strength-
duration time constant was 0.48 ± 0.01 μs and therheobase current 2.87 ± 0.14 mA. Neither flupirtine (200
mg p.o.) nor placebo affected these measures of excit-
ability (Table 2).
Consistent with observations made in vitro, RRP in
motoaxons to APB was reduced 2 hours after oral flupir-
tine (200 mg p.o.; baseline 3.40 ± 0.07 ms versus flupir-
tine 3.23 ± 0.09 ms; p < 0.01 paired t-test; see
Figure 3B&C and Table 2) but not placebo (3.45 ± 0.12
ms, p = 0.53). Oral flupirtine also reduced refractoriness
at 2 ms and 2.5 ms (Figure 3D&E and Table 2). In contrast
to the effect of flupirtine in vitro, the magnitude of super-
excitability at both 5 and 7 ms determined in vivo was not
affected by flupirtine (200 mg p.o; Figure 3F&G). Flupir-
tine and placebo were also both without effect on de-
and hyperpolarizing threshold electrotonus in vivo
(Table 2).
Recordings from APB during ischemia
Cuff-induced (200 mmHg) ischemia, induced a substan-
tial increase in surface EMG activity in all 20 subjects
(Figure 4A). EMG activity began on average 68.25 ± 8.72
s after cuff inflation and persisted for 288.65 ± 22.93 s.
The total rectified integrated EMG during the baseline
period of ischemia was 1.08 ± 0.12 V.s and this was
reduced to 0.80 ± 0.08 V.s (p < 0.01, paired t-test) 2 hours
after flupirtine (200 mg) but not placebo (0.98 ± 0.13 V.s;
p = 0.29).
Interestingly, in eleven subjects an increase in surface
EMG was also observed in the post-ischemic period
(Figure 4A). Post-ischemic EMG activity began on
average 125.80 ± 21.11 s after release of the cuff, per-
sisted for 295.20 ± 27.85 s and the total rectified inte-
grated EMG in the 10 minute period following release
of the cuff was 0.85 ± 0.10 V.s. Consistent with its
effect on EMG activity in the peri-ischemic period,
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http://www.translational-medicine.com/content/11/1/34flupirtine also reduced total integrated EMG activity in
the post-ischemic period (200 mg p.o.; 0.58 ± 0.05 V.s;
p = 0.023 paired t-test, see Figure 4D&E) and this ef-
fect was not significant following placebo (0.72 ± 0.09
V.s; p = 0.24).
Under baseline conditions, the surface EMG signal
recorded in the post-ischemic period exhibited pro-
nounced high frequency motor unit action potential
discharges (MUAP; see insets in Figure 4A&D). The
uniformity of MUAP shape and grouping of these
discharges suggest that they arose from repetitivedischarges in single motor units. The incidence of such
high frequency burst discharges was higher in the post-
ischemic period than during ischemia. This is evident
in the running power spectral density plots shown
below the raw EMG traces in Figure 4A&D. Following
flupirtine, post-ischemic high frequency repetitive dis-
charges are also evident in surface EMG recordings
however the length of each burst was curtailed
(Figure 4D, inset). The tendency for flupirtine to cur-
tail high frequency motor unit discharge is shown in
the normalised power spectral density plots (PSD;
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Figure 4 Effect of oral flupirtine and placebo on postischemic ectopic axonal discharge in motoneurones to abductor pollicis brevis in
healthy subjects. Representative EMG activity recorded from APB in a single subject before during (grey shading) and after a period of ischemia
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200Hz band for post-ischemic discharge is reduced
following flupirtine (Figure 4F).
Assessment of sensations during and after ischemia
Cuff-induced ischemia affects both motor and sensory
axons. To assess the sensory component, a visual
analogue scale (VAS) was used to rate the intensity of
painful sensations during and after ischemia. The VAS
comprised a 0 point anchor indicating no pain and an
anchor at 100 as the most intense pain imaginable. Aver-
aged across three baseline recordings, pain was rated at
31.1 ± 20.9 mm during ischemia and 33.2 ± 25.4 mm in
the postischemic period (Figure 5A). Two hours after
oral flupirtine (200 mg) the average ischemic pain rating
was 23.2 ± 16.8 mm VAS, (p = 0.12 paired t-test) and19.6 ± 20.3 mm in the post-ischemic period (-41%, p =
0.03). Oral placebo did not change either the ischemic
(30.5 ± 20.6 mm VAS, -1.7%, p = 0.70 paired t-test) nor
the post-ischemic pain rating (32.8 ± 27.1 mm VAS, -1.2%,
p = 0.69; Figure 5A).
The SF-MPQ was used to assess the intensity and
quality of sensations arising in the 10 minute period fol-
lowing release of the cuff. Under baseline conditions,
total rating index in the postischemic period was 14.1 ±
1.5 with a sensory and affective component scores of
11.0 ± 1.2 and 3.1 ± 3.0 respectively (Figure 5B). Two
hours after flupirtine (200 mg p.o.) the total intensity
rating (−45% to 7.8 ± 1.0, p < 0.01, paired t-test) and
sensory component scores were reduced (-48%, 5.8 ±
0.7, p < 0.01, paired t-test). In contrast, total intensity
ratings were not affected 2 hours after oral placebo
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Figure 5 Subjective rating of sensations perceived during and after ischemia of the arm. Visual analogue scale ratings (A) were
determined at rest (Baseline), at the end of a 10 minute period of ischemia (peri-ischemic) and 10 minutes after releasing the cuff (post-ischemic).
While at rest there was no significant difference between groups, in the peri- and postischemic phase treatment did have an effect. Especially in
the post-ischemic period application of flupirtine (200 mg p.o.) 2 hours prior to the experiment led to a significant decrease in intensity of
sensations (-41%, p = 0.03). Sensations perceived in the postischemic period were additionally assessed with the McGill Pain Questionnaire (SF-MPQ;
B&C). The total SF-MPQ score (TPRI) comprises both sensory (SPRI) and affective (APRI) components (B) and each were determined under control (filled
bars) conditions and 2 hours after a single oral dose of flupirtine (open bars) or placebo (grey bars). Flupirtine significantly reduced TPRI
(−45%; p < 0.01) and SPRI (-48%; p < 0.01). The SF-MPQ associative verbal descriptors (C) were also determined under control conditions
(filled) and 2 hours after a single oral dose of flupirtine (200 mg; open) or placebo (grey). Under baseline conditions, the average rating of
‘throbbing’, ‘shooting’, ’stabbing’, ‘sharp’ and ‘hot-burning’ during ischemia was mild-moderate (filled). For the affective descriptors, only ‘sickening’ was
rated as moderate. Oral flupirtine (200 mg p.o.) reduced the ratings of ‘hot-burning’ (p < 0.01) and ‘throbbing’(p = 0.04) from moderate to mild.
Accordingly to the effect on sensory components, application of flupirtine led to a reduction of several sensory descriptors.
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descriptors to qualitatively describe sensations. Under
baseline conditions, the average rating of ‘throbbing’,
‘shooting’, ’stabbing’, ‘sharp’ and ‘hot-burning’ during
ischemia was mild-moderate (Figure 5C). For the affective
descriptors, only ‘sickening’ was rated as moderate. Two
hours after oral flupirtine (200 mg p.o.) the ratings of
‘hot-burning’ (p < 0.01 Kruskal-Wallis) and ‘throbbing ’
(p = 0.04) were reduced from moderate to mild.
Discussion
Strength and limitations
The primary strength of this study examining drug-induced
effects on axonal excitability in vivo and in vitro is the abil-
ity to compare and thus judge target engagement and theefficacy of pharmacological compounds on peripheral mye-
linated axons. In particular, the ability to expose nerve seg-
ments to high concentrations provides a basis for the
interpretation of subtle changes in excitability detected in
people in situ, where dose is limited.
Segments of human nerve material were obtained at biopsy
and are thus potentially pathological. Previous experiments
indicate however that the electrical excitability of nerve fasci-
cles obtained from patients at biopsy is not correlated in a
systematic way with the underlying pathology [25,26].
Generalizability
A common deficit encountered during the clinical and
pre-clinical development phases of pharmacological com-
pounds targeting peripheral nerve is the inability to
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this, standardized measures of axonal excitability were
used to examine the effect of flupritine on human periph-
eral nerve in vitro and in situ. Demonstrable changes in
the excitability of myelinated axons were observed in vitro
(Figure 2) and in motoraxons in situ (Figure 3). This
confirmation of target engagement was shown to be
therapeutically relevant with flupirtine suppressing ectopic
axonal activity evoked by ischemia (Figure 4).
Interpretation
Kv7.2 subunits were identified nodally in large diameter
myelinated axons in human sural nerve (Figure 1) consistent
with previous reports using myelinated rat axons [6,8,9].
Kv7.2 expression was also evident along unmyelinated axons
[27] where it is also postulated to regulate excitability (6)
and suppress axonal discharge [28]. From voltage clamp
studies performed on single nodes of Ranvier of myelinated
axons from human nerve, it is possible that up to 30% of
the slow potassium current may be active at rest [6]. Since,
flupirtine shifts the voltage-dependent activation of cell-
expressed Kv7.2 in the hyperpolarizing direction [29] it
would be expected to hyperpolarize axons by increasing the
number of open Kv7 channels at resting membrane poten-
tials around −60 to −70 mV. For the human myelinated
axons examined here, flupirtine (3-30μM) produced a
concentration-dependent shortening of the relative refrac-
tory period and an increase in post-spike superexcitability
in vitro, as well as a comparable reduction in the RRP
in vivo (2 hours after oral flupirtine).. The increase in post-
spike superexcitability seen in vitro (Figure 2C) was
only apparent for flupirtine concentrations above 10
μM (Figure 2F,G). Previous reports indicate that the
peak plasma concentration of flupirtine reaches
values in the range of 5 to 6.5 μM, 2 hours after oral
flupirtine 200 mg; [30-32]. This concentration is
below that at which effects can be detected in vitro
and potentially accounts for the lack of effect of flu-
pirtine on the superexcitable phase in motor axons as
well as the modest effect of flupirtine on the RRP
in vivo (Figure 3B,C).
The modest reduction in the value of the relative re-
fractory period in motoraxons to APB may well be
secondary to a change in temperature, specifically a
warming of peripheral nerve. Propofol was recently
reported to shorten the relative refractory period in
motoaxons and this effect was attributed to a non-
specific increase in skin temperature [33]. Although no
global differences in skin temperature were detected
between baseline, placebo and flupirtine recording
sessions, flupirtine could potentially lead to a warming
of peripheral nerve either directly by relaxing vascular
smooth muscle [34] or indirectly through suppression of
activity in sympathetic neurones [35].The only other study examining the effects of flupir-
tine on peripheral axons in people used a 400 mg oral
dose and they reported no change in soleus H-reflex la-
tency but a reduction in medium latency flexor reflex
responses evoked with 5 pulses at 200 Hz [36]. It is pos-
sible that this effect of flupirtine reflects the ability of
slow axonal potassium channels to suppress high fre-
quency discharge.
Flupirtine is however also reported to act as an agonist
at GABAA receptors in DRG neurones [37]. While an
agonist action of flupritine at GABAA receptors may
contribute to flupritine’s ability to alter spinal reflex la-
tency, peripheral axons maintain a high intra-axonal
chloride concentration and thus activation of GABAA
receptors alone cannot account for an increase in post-
spike superexcitability or a shortening of the relative re-
fractory period in peripheral myelinated axons.
Interestingly, post-spike recovery cycles recorded from
myelinated sural nerve axons in vitro (Figure 1B) appear
to lack the late phase of sub-excitability (between ca. 7
and 100 ms) which is otherwise prominent in recovery
cycles from median nerve motor axons in vivo (Figure 2B).
Recordings in people indicate that late sub-normality is
typically smaller in sural nerve than it is in median nerve
[38] and that, sural axons thus have less slow nodal potas-
sium channels (Kv7) [38].
Post-ischemic EMG activity arises axonally [39,40] and
for a 10 minute period of ischemia affects predominantly
myelinated axons [41,42]. In myelinated sensory axons,
ectopic activity produces paraesthesias and in motor
axons fasciculations are observed [42], with the former
being more susceptible due to a more pronounced per-
sistent nodal sodium current [43]. During the period of
ischemia, ectopic activity in myelinated axons is typically
attributed to a protracted axonal depolarization arising
chiefly from a reduction in electrogenic Na+/K+-ATPase
activity and possibly a resultant accumulation of extra-
cellular potassium, particularly in the adaxonal space
[44]. Activation of slowly activating, non-inactivating
Kv7 channels by flupirtine should adequately counter
slow depolarization and indeed flupirtine effectively
reduced total EMG activity during ischemia (Figure 4).
Post-ischemic EMG activity comprises high frequency
components (Figure 4) and microneurographic record-
ings from myelinated axons in people following ischemia
also show prominent high frequency burst discharges ca.
200 Hz; [41,42]. Although high frequency bursts still
occurred in the post-ischemic period following flupir-
tine, there was a reduction in the burst duration, i.e.
number of impulses (Figure 4). Flupirtine’s (200 mg p.o)
curtailing of action potential burst length in human
motoneurones is consistent with previous observations
in rat peripheral myelinated axons using retigabine [6]
and hippocampal CA1 neurones [45] and suggests that
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ectopic bursts in peripheral axons.
Changes in the excitability of peripheral myelinated
axons in people (Figures 2 and 3) were comparable with
those seen in vitro using human sural nerve segments,
suggesting that flupirtine affects Kv7 subunits expressed
in peripheral nerve.
Conclusion and clincial implications
The synthetic Kv7-channel activator flupirtine has been
used clinically in Europe for over two decades and its
analgesic effects have long been associated with an ac-
tion on neurones in the CNS. Using a unique combin-
ation of in vitro and in vivo methodologies, the clinical
profile of flupirtine is shown here to extend to effects on
peripheral myelinated axons, reducing their excitability
and suppressing aberrant post-ischemic axonal dis-
charge. This highlights the potential benefit of Kv7 chan-
nel activators for clinical strategies aimed at reducing
hyperexcitability and ectopic discharge in peripheral
axons.
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